Related Experiment Video
Updated: May 15, 2026
Studying Triple Negative Breast Cancer Using Orthotopic Breast Cancer Model
Published on: March 20, 2020
Antitumor effect of FP3 in a breast cancer xenograft model
Huanrong Lan1, Lingzhi Zheng, Ketao Jin
1Departments of Plastic Surgery.
Abstract:
FP3 is a novel vascular endothelial growth factor (VEGF) blocker proposed to have antiangiogenic properties. Previous studies revealed that FP3 is a new promising agent for treating human choroidal neovascularization (CNV)-associated age-associated macular degeneration (AMD) and has an inhibitory effect on VEGF-mediated proliferation and migration of human umbilical vein endothelial cells and VEGF-mediated vessel sprouting of the rat aortic ring in vitro. Previous studies have also revealed that FP3 has antitumor effects and antiangiogenic effects in a non-small cell lung cancer cell line (A549), as well as in patient-derived tumor tissue xenograft models of gastric cancer and colon carcinoma with lymphatic and hepatic metastases in nude mice. In the present study, the antitumor effect of FP3 in an MDA-MB-231 breast cancer xenograft model was investigated. Treatment with FP3 for 3 weeks significantly suppressed xenograft growth and this inhibition was associated with a significant decrease in angiogenesis and direct inhibition of tumor cells. The results of the present study indicate that FP3 inhibits breast cancer tumor growth via the indirect inhibition of angiogenesis as well as a direct effect on tumor cells.
Insights
FP3, a vascular endothelial growth factor (VEGF) blocker, effectively inhibits breast cancer tumor growth. This novel agent demonstrates antiangiogenic and direct antitumor effects in preclinical models.
Area of Science:
- Oncology
- Vascular Biology
- Pharmacology
Background:
- Vascular endothelial growth factor (VEGF) plays a crucial role in angiogenesis, which is vital for tumor growth and metastasis.
- FP3 is a novel VEGF blocker with demonstrated antiangiogenic properties in various in vitro and in vivo models.
- Previous research suggests FP3's potential in treating conditions like age-related macular degeneration and various cancers.
Purpose of the Study:
- To investigate the antitumor effect of FP3 in an MDA-MB-231 breast cancer xenograft model.
- To determine if FP3 inhibits breast cancer growth through antiangiogenic mechanisms or direct effects on tumor cells.
Main Methods:
- Treatment of MDA-MB-231 breast cancer xenografts in mice with FP3 for 3 weeks.
- Assessment of xenograft growth, angiogenesis, and direct tumor cell effects.
Main Results:
- FP3 treatment significantly suppressed xenograft tumor growth.
- Inhibition of tumor growth was associated with a significant decrease in angiogenesis.
- FP3 demonstrated direct inhibitory effects on tumor cells.
Conclusions:
- FP3 exhibits significant antitumor effects in a breast cancer xenograft model.
- FP3 inhibits breast cancer growth by both reducing angiogenesis and directly affecting tumor cells.
- FP3 represents a promising therapeutic agent for breast cancer treatment.
